Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 17/20 | 0.50 |
| ▸ | SOAT2 | O75908 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.50 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | PTGIR | P43119 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10197585 | 0.89 | PARP1 (0.46) | PARP1DGAT1SOAT2CYP2C9SOAT1 | |
| SCHEMBL13190420 | 0.82 | PARP1 (0.53) | PARP1PDE3BPDE3A | |
| SCHEMBL409806 | 0.82 | DGAT1 (0.55) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL409807 | 0.82 | DGAT1 (0.55) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL10197583 | 0.72 | DGAT1 (0.72) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL10197577 | 0.71 | DGAT1 (0.47) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL13190491 | 0.71 | DGAT1 (0.57) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL384873 | 0.71 | DGAT1 (0.54) | DGAT1SOAT2SOAT1DGAT2 | |
| SCHEMBL405067 | 0.71 | DGAT1 (0.54) | DGAT1SOAT2SOAT1DGAT2 | |
| SCHEMBL532993 | 0.70 | PARP1 (0.80) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010107768-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | PARP1 1511/4885DGAT1 2/4885SOAT2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.